Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 11/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 9/20 | 0.43 |
| ▸ | GPR6 | P46095 | 2/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2424276 | 0.93 | PRKCZ (0.45) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL2422864 | 0.91 | CYP1A2 (0.52) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL2425868 | 0.89 | ROCK2 (0.45) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL13087722 | 0.85 | PRKCZ (0.56) | CYP1A2CYP2C19HSD17B10CLK4PRKCZ | |
| SCHEMBL13087336 | 0.85 | PRKCZ (0.56) | CYP1A2CYP2C19HSD17B10CLK4PRKCZ | |
| SCHEMBL2430796 | 0.84 | IRAK4 (0.48) | CLK4IRAK4 | |
| SCHEMBL2422828 | 0.84 | ROCK2 (0.48) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL3628367 | 0.84 | ROCK2 (0.47) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL15172413 | 0.83 | PRKCZ (0.43) | CYP1A2CYP2C19HSD17B10CLK4ROCK2 | |
| SCHEMBL2430099 | 0.83 | IRAK4 (0.45) | CLK4ROCK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366699-B1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2366699-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010038465-A1 | 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF | 旭化成ファーマ株式会社 (JP) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | CYP1A2 2622/4885CYP2C19 4781/4885HSD17B10 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.